Trial reportHaematologica2017
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Trial report in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma
Phase II Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL.Blood advances · 2021Trial
- Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas.Leukemia & lymphoma · 2019Trial
- Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.British journal of haematology · 2018Trial
- Real-world data on long-term outcomes in patients with T-cell lymphomas: a nationwide study of Korea.Blood research · 2025Article
- Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.Blood advances · 2024Article
- Treatment of Adult T-Cell Leukemia/Lymphoma: Established Paradigms and Emerging Directions.Current treatment options in oncology · 2023Review
- First-Line Therapy for Nodal T-cell Non-Hodgkin Lymphomas: an Unmet Need in Hematology.Current oncology reports · 2023Review
- Moving towards biologically informed treatment strategies for T-cell lymphomas.International journal of hematology · 2023Review
- Review
- Peripheral T-Cell Lymphomas: Therapeutic Approaches.Cancers · 2022Review
- Chemotherapy Plus RadiotherapyFrontiers in oncology · 2021Article
- Updates in the Treatment of Peripheral T-Cell Lymphomas.Journal of experimental pharmacology · 2021Review
- Strategies for aggressive T-cell lymphoma: divide and conquer.Hematology. American Society of Hematology. Education Program · 2020Review
- Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.International journal of hematology · 2020Article
- Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma.International journal of hematology · 2020Article
- Controversies in the Treatment of Peripheral T-cell Lymphoma.HemaSphere · 2020Review
- Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.Blood advances · 2020Review
- Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis.OncoTargets and therapy · 2019Article
- EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma.International journal of hematology · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The standard CHOP therapy for peripheral T-cell lymphoma has resulted in unsatisfactory outcomes and it is still not clear what is the optimal front-line therapy. We conducted a multicenter phase II study of dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone (EPOCH) for untreated peripheral T-cell lymphoma patients. In this prospective study, 41 patients were treated with dose-adjusted-EPOCH as initial therapy: peripheral T-cell lymphoma-not otherwise specified, n=21; angioimmunoblastic T-cell lymphoma, n=17; anaplastic lymphoma kinase-positive anaplastic large cell lymphoma, n=2; and anaplastic lymphoma kinase-negative anaplastic large cell lymphoma, n=1. Median patient age was 64 years (range: 32-79 years). According to the International Prognostic Index criteria, 51.2% were at high-intermediate or high risk. The overall response and complete response rates were 78.0% [95% confidence interval (CI): 62.4-89.4%] and 61.0% (95%CI: 44.5-75.8%), respectively. At the median follow up of 24.0 months, the 2-year progression-free survival and overall survival were 53.3% (95%CI: 36.4-67.5%) and 73.2% (95%CI: 56.8-84.1%), respectively. The younger patients (≤ 60 years old) had a high response rate (overall response 94.1% and complete response 70.6%) and survival rate (progression-free survival 62.5% and overall survival 82.4%). The most common grade ≥ 3 adverse events were neutropenia (74.5%), anemia (40.8%), thrombocytopenia (22.0%), and febrile neutropenia (9.0%). Dose-adjusted-EPOCH had a high response rate with a tolerable toxicity profile. Our results indicate that dose-adjusted-EPOCH is a reasonable first-line approach for peripheral T-cell lymphoma patients and may improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.